American Society for Reproductive Medicine
Since 2016, Erol Onel has served as the vice president of Heron Therapeutics in California. In this capacity, he oversees the development of a non-opioid pain drug and creates clinical strategies and plans. Over the course of his more than 20-year career, Dr. Erol Onel has belonged to several professional organizations, including the American Society for Reproductive Medicine.
Dedicated to promoting and advancing the reproductive medicine field, the American Society for Reproductive Medicine (ASRM) provides its members with a variety of benefits. Below is a brief sampling of the resources made available to ASRM members:
– News and education: members of the ASRM are granted access to two Society journals, the Journal of Assisted Reproduction and Genetics and Fertility and Sterility. Beyond that, members are capable of earning both CME and CE credits through ASRM eLearn or at an in-person education event. Members also receive printable ethics statements and practice guidelines.
– Specials and discounts: ASRM provides its members with special rates on a wide range of products and services. Registration fees for the ASRM Scientific Congress and Expo are reduced for Society members and the organization’s eLearn platform features free courses.
– Members-only online resources: in addition to each member having access to an online login account, the organization also maintains a digital directory of all its members and offers answers for potential CPT coding questions through its Coding Corner. Further, members can post jobs on the ASRM Career Center at a discounted price.
– Professional development: small group meetings and online listservs for members provide professionals with a variety of networking opportunities. ASRM maintains several member groups that professionals can participate in and also provides patients with an easy-access directory to find practitioners in the field. Members are also eligible for awards and grants from ASRM.
Dr. Erol Onel serves as vice president of Heron Therapeutics, a pharmaceutical research and development company based in La Jolla, California. Outside of work, Dr. Erol Onel remains committed to giving back. Every year on September 11, he tries to give blood to pay tribute. Donating blood helps save lives while also providing health benefits for the people who regularly donate.
One of the biggest health benefits is a lower risk of cancer. Donating blood reduces levels of iron in the body and helps maintain healthy levels. Lower iron levels are linked to lower risk of cancer. In addition, reduced levels of iron can have benefits for the liver and pancreas, which store excesses of the mineral. Excess iron stored in these organs can lead to liver failure, cirrhosis, and pancreatic damage.
In addition, repeated donations can help lower blood viscosity so that it flows better through blood vessels. The result is fewer arterial blockages. Research in the American Journal of Epidemiology found that blood donors are 88 percent less likely to have a heart attack.
American Urological Association
A physician and pharmaceutical researcher, Dr. Erol Onel serves as the vice president of Heron Therapeutics, Inc. In this capacity, he works with a team of professionals as they seek approval for a long-acting non-opioid drug. Over the years, Dr. Erol Onel has belonged to several professional organizations, including the American Urological Association (AUA).
Dedicated to improving urologic care through research, policy, and education, the AUA recently released new joint clinical guidelines for the treatment of stress urinary incontinence (SUI). This condition affects nearly 50 percent of women in the United States and is signified by involuntary urine leakage due to sneezing, laughing, or other activities that increase abdominal pressure. In many cases, women opt for surgical treatment of SUI symptoms.
The AUA wrote the joint evidence-based guidelines for surgical treatment with the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU). They include a total of 24 treatment recommendations, including alternatives to various surgical options and information about determining when additional evaluations are needed to confirm SUI. A panel of SUI experts worked on creating the clinical guideline, and it was subject to 93 peer reviews before being approved and released by the AUA and SUFU.
As vice president at Heron Therapeutics in La Jolla, California, Dr. Erol Onel directs the company’s pain franchise. Currently in leadership of a team charged with approval of a new non-opioid drug, Dr. Erol Onel works on a national and global level.
For patients with pain, non-opioid analgesics and anti-inflammatory drugs can help to interrupt the pain signal process. Unlike opioids, they usually do not work directly on the central nervous system, but rather act at the peripheral level.
Non-steroidal anti-inflammatory drugs (NSAIDs) block the COX-1 and COX-2 enzymes that are key players in the pain process. NSAIDs reduce the sensation of pain as well as inflammation.